布达鲁单抗治疗中重度斑块状银屑病的长期疗效与安全性:AMAGINE-2与-3的事后汇总分析
本文汇总AMAGINE-2与-3两项3期试验中接受布达鲁单抗210mg每2周持续治疗的中重度斑块状银屑病患者数据,评估至第120周的疗效与安全性。基于观察数据,第120周时86%的患者达到PASI 90、74%达到PASI 100,第12周58%的患者绝对PASI≤1、第52周约80%且维持至第120周。安全性至第120周与主研究结果相当。
要点
- 持续布达鲁单抗210mg组第120周观察数据PASI 90为86%、PASI 100为74%。
- 第12周绝对PASI≤1者为58%,第52周约80%并维持至第120周。
- 中位暴露747天,每100患者年治疗中出现不良事件暴露调整事件率为329。
核心结论
- 布达鲁单抗治疗耐受性良好,可快速达到并维持高水平皮损清除至第120周,支持其长期疗效与安全性特征。
研究设计与样本
- 对AMAGINE-2与-3两项3期试验中接受持续布达鲁单抗210mg每2周,或经布达鲁单抗140mg或安慰剂治疗12周后换用布达鲁单抗210mg每2周的中重度斑块状银屑病患者进行安全性及疗效数据汇总分析。
- 疗效数据采用观察数据、无应答者填补(NRI)及NRI与随机缺失假设相结合的方法处理缺失数据。
- 绝对PASI评分采用混合效应模型重复测量建模及多重填补呈现。
主要发现
- 基于第120周观察数据,持续布达鲁单抗210mg组86%达到PASI 90、74%达到PASI 100。
- 该组第12周58%达到绝对PASI≤1,第52周该比例增至约80%并维持至第120周。
- 持续布达鲁单抗210mg组中位暴露时间为747天,每100患者年治疗中出现不良事件的总体暴露调整事件率为329。
- 至第120周的安全性结果与AMAGINE-2与-3主研究结果相当。
- 经布达鲁单抗140mg或安慰剂治疗12周后换用布达鲁单抗210mg的患者显示出相似的皮损清除与安全性特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brodalumab is a monoclonal antibody that blocks multiple interleukin (IL)-17 family cytokines by binding to the shared A subunit of the IL-17 receptor. In Phase 3 trials, brodalumab provided high levels of skin clearance through 52 weeks in patients with moderate-to-severe psoriasis and was generally well tolerated. OBJECTIVES: To assess efficacy response rates and safety outcomes through 120 weeks for patients with moderate-to-severe psoriasis who received brodalumab. METHODS: Safety and efficacy data were pooled for patients from AMAGINE-2 and -3 who received continuous brodalumab 210 mg every 2 weeks, or brodalumab 210 mg every 2 weeks after receiving either brodalumab 140 mg or placebo through Week 12. Efficacy data are presented using observed data, non-responder imputation (NRI) and a combination of NRI and missing at random assumption to account for missing data. Absolute PASI scores are presented using mixed-effect model repeated measure modelling and multiple imputation. RESULTS: Based on observed data at Week 120, 86% of the continuous brodalumab 210 mg group achieved PASI 90 and 74% achieved PASI 100. At Week 12, 58% of this group achieved absolute PASI ≤1; this proportion increased to approximately 80% at Week 52 and persisted through Week 120. Among patients receiving continuous brodalumab 210 mg, median duration of brodalumab exposure was 747 days and the overall exposure-adjusted event rate of treatment emergent adverse events per 100 patient-years was 329. Safety through 120 weeks was comparable to the results of the primary AMAGINE-2 and -3 studies. Patients who switched to brodalumab 210 mg after receiving either brodalumab 140 mg or placebo through Week 12 showed similar skin clearance and safety profiles. CONCLUSIONS: Brodalumab treatment was well tolerated and resulted in high levels of skin clearance that were rapidly achieved and maintained through Week 120, supporting its long-term efficacy and safety profile.
引用
- Reich K, Iversen L, Puig L, et al. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2022. PMID: 35279890. doi:10.1111/jdv.18068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。